Skip to content

Study · In vitro (cells) · 1997

3 results

Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells.

Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y

The Journal of biological chemistry1 Jun 1997Cited by 39 (Europe PMC)

PMID9195961 (opens in a new tab)DOI10.1074/jbc.272.26.16514 (opens in a new tab)PepBankPUB-09195961
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The function of cell surface-associated insulin-like growth factor-binding proteins (IGFBPs) is controversial. Both inhibition and facilitation of IGF action as well as IGF-independent effects have been reported. We examined the influence of endogenous cell surface-associated IGFBPs on IGF-I receptor (IGF-IR) function in Ishikawa endometrial cancer cells by comparing the effects of IGF-I and its truncated analog des-(1-3)-IGF-I on several components of the IGF-IR signal transduction pathway in the absence of significant amounts of soluble IGFBPs. IGF-I and des-(1-3)-IGF-I are known to have similar affinities for IGF-IR, although the affinity of des-(1-3)-IGF-I for IGFBPs is greatly reduced. Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs. In contrast, des-(1-3)-IGF-I manifested a remarkably higher potency as compared with IGF-I in inducing short and middle term cellular responses in IGF-IR-transfected Ishikawa endometrial cancer cells possessing a high number of both the receptor and the cell membrane-bound IGFBP-3. Thus, this difference in the effects of IGF-I and des-(1-3)-IGF-I can be attributed to the attenuation of IGF-I-mediated IGF-IR signaling by membrane-bound IGFBP-3.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In NIH 3T3 cells overexpressing IGF-IR, des-(1-3)-IGF-I and IGF-I were equipotent in receptor binding.

    In plain wordsIn cells, des-(1-3)-IGF-I and IGF-I had equal potency for receptor binding.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeIGF-IR binding potency
    Study

    n: not reported in source

    NIH 3T3 cells overexpressing IGF-IR
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs.
  2. 02LabIn vitro (cells)Activity measurement

    In NIH 3T3 cells overexpressing IGF-IR, des-(1-3)-IGF-I and IGF-I were equipotent in receptor activation.

    In plain wordsIn cells, des-(1-3)-IGF-I and IGF-I had equal potency for receptor activation.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeIGF-IR activation potency
    Study

    n: not reported in source

    NIH 3T3 cells overexpressing IGF-IR
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs.
  3. 03LabIn vitro (cells)Activity measurement

    In IGF-IR-transfected Ishikawa cells, des-(1-3)-IGF-I induced short and middle term cellular responses more potently than IGF-I.

    In plain wordsIn cells, des-(1-3)-IGF-I induced short and middle term responses more potently than IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseShort and middle term cellular response potency
    Study

    humann: not reported in source

    IGF-IR-transfected Ishikawa endometrial cancer cells
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, des-(1-3)-IGF-I manifested a remarkably higher potency as compared with IGF-I in inducing short and middle term cellular responses in IGF-IR-transfected Ishikawa endometrial cancer cells possessing a high number of both the receptor and the cell membrane-bound IGFBP-3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.